Navigation Links
VirtualScopics Schedules Second Quarter 2009 Earnings Announcement
Date:7/28/2009

ROCHESTER, N.Y., July 28 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. (Nasdaq: VSCP), a leading provider of quantitative imaging for clinical trials, today announced that on Wednesday, August 12, 2009 it will release its second quarter 2009 financial results. The company will host a conference call to discuss these results on Thursday, August 13, 2009 at 11:00 a.m. EDT.

VirtualScopics' President and Chief Executive Officer, Jeff Markin, and Chief Business and Financial Officer, Molly Henderson, will provide a business update and discuss the company's results for the quarter ended June 30, 2009 during the conference call.

Interested participants should call 888-352-6795 when calling within the United States or 719-325-2192 when calling internationally. This call can also be accessed at www.virtualscopics.com and will be available for 30 days after the call.

About VirtualScopics, Inc.

VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit www.virtualscopics.com.

Forward-Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the backlog and new customer awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov. These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to awards of contracts currently under negotiation, the risk that they may not get signed. Other risks include the company's dependence on its largest customers and risks of contract performance. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.

    CONTACT:
              Molly Henderson
              Chief Business and Financial Officer
              500 Linden Oaks
              Rochester, New York 14625
              (585)249.6231


'/>"/>
SOURCE VirtualScopics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. VirtualScopics Reports Record Revenue
2. VirtualScopics Regains NASDAQ Compliance
3. VirtualScopics Reports Record Revenues and Gross Profit in the First Quarter
4. VirtualScopics Schedules First Quarter 2009 Earnings Announcement
5. VirtualScopics Scientists to Present at International Society for Magnetic Resonance in Medicine 17th Scientific Meeting and Exhibition
6. VirtualScopics Receives Further Extension to Regain Compliance With Nasdaq
7. VirtualScopics to Present at 11th Annual BIO CEO & Investor Conference
8. VirtualScopics Backlog Rises to a Record $27 Million
9. VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit
10. VirtualScopics to Present at Two Upcoming Investor Conferences
11. VirtualScopics Schedules Third Quarter 2008 Earnings Announcement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... Viejo, CA (PRWEB) , ... July 20, 2017 , ... ... when placed between two clips in the FCPX timeline. This effect isolates horizontal and ... transition in this package contains either a rotating or flipping animation and can be ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... Houston, is pleased to announce their expansion to the Midwest with the establishment ... Alysse Hollis and Ronald Bell, and of counsels, John Peck and Robert Bruns, ...
(Date:7/20/2017)... ... ... Doctors on Liens, the leading network of medical providers working on a lien ... Horine, DC to their exclusive list of medical professionals. Horine Chiropractic is a unique ... clinic director and his son Dr. Lee Horine and daughter-in-law Dr. Natalie Horine serving ...
(Date:7/20/2017)... ... July 20, 2017 , ... The Dermatology Clinic announced today the addition ... BS in Biology from LSU, graduating summa cum laude. He attended Emory University School ... residency in St. Louis, Dr. Dunbar moved to New York to complete an AGCME-accredited ...
(Date:7/20/2017)... CA (PRWEB) , ... July 20, 2017 , ... ... of travel protection services since 2014, top travel insurance solution company VisitorsCoverage Inc. ... tools to sell all major international travel insurance products online, under their own ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... 2017  Sysmex America, Inc., a leading provider ... as well as middleware information systems technology, today ... quality assurance easier and more risk free than ... for the innovation that it delivers to the ... assurance processes to a new level with automated, ...
(Date:7/11/2017)... JERUSALEM , July 11, 2017 Oramed ... ), a clinical-stage pharmaceutical company focused on the development ... U.S. Food and Drug Administration (FDA) has agreed to ... successfully completed Phase IIb trial of its oral insulin ... The Phase IIb trial met primary and secondary endpoints ...
(Date:7/10/2017)... 2017 The Institute for In Vitro Sciences ... recipient of a VITROCELL® inhalation exposure system thanks to ... The device, which is designed to replace animals in ... cells to airborne test materials in an environment that ... system for testing combustible tobacco products, as well as ...
Breaking Medicine Technology: